Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907766 | 0.80 | ERCC1 (0.44) | P2RX7KCNH2GRM2 | |
| SCHEMBL3905975 | 0.79 | KCNH2 (0.46) | KCNH2GRM2POLBMEN1ALDH1A1 | |
| SCHEMBL3901558 | 0.78 | KCNH2 (0.44) | KCNH2GRM2POLBMEN1ALDH1A1 | |
| SCHEMBL3914699 | 0.78 | P2RX7 (0.49) | P2RX7KCNH2GRM2POLBMEN1 | |
| SCHEMBL3908475 | 0.77 | ERCC1 (0.52) | P2RX7KCNH2GRM2MEN1ALDH1A1 | |
| SCHEMBL3908186 | 0.77 | ERCC1 (0.43) | KCNH2POLBALDH1A1KMT2A | |
| SCHEMBL4334048 | 0.76 | P2RX7 (0.40) | P2RX7 | |
| Hydrochloric Acid SCHEMBL4330984 | 0.76 | P2RX7 (0.39) | P2RX7POLB | |
| SCHEMBL3908193 | 0.75 | ERCC1 (0.41) | KCNH2ALDH1A1 | |
| SCHEMBL3908182 | 0.74 | FAAH (0.37) | P2RX7KCNH2GRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | DHPS, DUT, CDKN1A | P2RX7 1553/4885KCNH2 1426/4885GRM2 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.